Referring to slide 5, OVERVIEW Novel approach (bullet point)Lead products based on synthetic form of a widely studied natural product which greatly enhances the probability of clinical and regulatory success
This statement is false and misleading. It is pure spin. Having a lead product based on the synthetic form of a widely studied natural product may greatly enhance BOT's CONFIDENCE in the probability of clinical and regulatory success but not probability of success as claimed. BOT claims its compound is a novel approach of its novel lead products. It still has to jump through the same hoops as every other product on its path to regulatory approval. The only shortcut available is, say, with the FDA by gaining Orphan Drug status pathway approval.
Referring to slide 5, OVERVIEW Novel approach (bullet point)...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |